Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

This study has been completed.
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company ) Identifier:
First received: April 20, 2007
Last updated: March 17, 2014
Last verified: March 2014
This study will investigate whether GC1008, an antibody which neutralizes TGF-beta, is safe in treating patients with the disease called focal segmental glomerulosclerosis (FSGS). The highest dose without excessive side effects will be investigated. Tests will determine how long GC1008 is in the body and how it is excreted.

Condition Intervention Phase
Focal Segmental Glomerulosclerosis
Biological: GC1008
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I, Multicentre, Open-label, Dose-escalating Study of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS)

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • To determine Safety and tolerability of single dose infusions of GC1008 in patients with treatment resistant idiopathic FSGS and nephrotic range proteinuria [ Time Frame: up to 2 years ] [ Designated as safety issue: No ]
  • Pharmacokinetics of GC1008 following a single dose infusion [ Time Frame: up to 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To investigate Effect of single dose infusions of GC1008 on biomarkers of clinical efficacy. [ Time Frame: up to 2 years ] [ Designated as safety issue: No ]

Enrollment: 16
Study Start Date: May 2007
Study Completion Date: February 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort A
Dose Group
Biological: GC1008
1 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
Experimental: Cohort B
Dose Group
Biological: GC1008
2 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
Experimental: Cohort C
Dose Group
Biological: GC1008
4 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
Experimental: Cohort D
Dose Group
Biological: GC1008
0.3 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.

Detailed Description:
Patients in each cohort will receive a single dose of GC1008 infusion at 1, 2, 4 or 0.3 mg/kg body weight. The higher dose cohort will not start until the first 28 days safety data for the lower dose cohort have been reviewed by the independent Data Monitoring Committee (DMC). Cohort C and D will run concurrently with patients randomised to receive either a 4 or 0.3 mg/kg body weight dose, respectively. After receiving the infusion of GC1008 on Day 0, patients will be monitored for the 24 hours following the infusion. Patients will return periodically over the following 112 days for safety evaluations and clinical outcome assessments. Blood samples will be collected to evaluate the pharmacokinetics of single dose administration of GC1008 as well as for evaluation of markers of clinical efficacy

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • GFR≥25ml/min/1.73m2 calculated by the MDRD equation
  • Urinary total protein: creatinine ratios >200mg/mmol derived from the average of 2 first morning voids taken during screening period
  • Biopsy confirmed as idiopathic FSGS by a central reviewer
  • Treatment resistance. NOTE:Patients to have received minimum 6 week course of steroids or immunosuppressant
  • If receiving treatment with an ACEi and/or ARB dose to be stable for a minimum of 4 weeks prior to randomization
  • Influenza vaccine (according to season)
  • Negative screening per American Cancer Society (ACS) 2003 guidelines, as appropriate to patient demographics and clinical status

Exclusion Criteria:

  • Secondary FSGS
  • steroid resistant patients who are unable to reduce their steroid dose to <10mg/day of prednisolone or equivalent 4 weeks prior to study dosing day
  • Positive serology for serious infections (including but not limited to infection with Hep B or C, HIV)
  • Concomitant illnesses:Diabetes Type I; Cardiac or Hepatic disease, HIV; Cancer, precancerous state (eg familial adenomatous polyposis; Any condition requiring treatment with other immunosuppressant drugs within 4 weeks prior to dosing day or during the course of the study
  • Pre-existing oral-pharyngeal disease (dental carries and other minor dental disease are acceptable)
  • Haemoglobin level of <9.0g/dL prior to dosing
  • Treatment with coumadin, anti-vitamin K analogues or low molecular weight heparins. Patients must have stopped treatment a minimum of four weeks prior to receiving study medication.
  • Patients requiring ongoing treatment with non-steroidal anti-inflammatory drugs (NSAIDs). Patients must have stopped treatment a minimum of four weeks prior to receiving study medication.
  • Patients who have had surgery/fracture within 3 months prior to dosing day
  • History of cancer unresolved within 5 years prior to screening or a known precancerous state; or any form of skin cancer either current or past history
  • Women who are pregnant, lactating or who plan to become pregnant within 4 months of infusion
  • Women of childbearing potential unless taking medically acceptable contraceptive
  • Men with female partners of childbearing potential unless they are taking medically acceptable contraceptive precautions
  • Use of any investigation drug administered as part of a clinical trial within 4 weeks prior to commencing screening
  • Other clinically significant, uncontrolled medical condition that in the investigator's opinion may interfere with the assessment or follow-up
  • Active ethanol or drug abuse, excluding tobacco use
  • Electrocardiogram (ECG) abnormalities considered to be clinically significant at screening
  • Unable to comply with the requirements of the study
  • Active thrombophlebitis, thromboembolism, hypercoagulability states, bleeding, or use of anticoagulation therapy (including anti-platelet agents). Patients with a history of deep venous thrombosis may participate if successfully treated, completely resolved, and no treatment has been given for >4 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00464321

United States, California
San Francisco, California, United States
United States, Minnesota
Rochester, Minnesota, United States
United States, New York
New Hyde Park, New York, United States, 11042-1433
United States, North Carolina
Chapel Hill, North Carolina, United States
Berlin, Germany
Duesseldorf, Germany
Solingen, Germany
Bergamo, Italy
United Kingdom
Cambridge, United Kingdom
Sponsors and Collaborators
Genzyme, a Sanofi Company
Study Director: Medical Monitor Genzyme, a Sanofi Company
  More Information

Responsible Party: Genzyme, a Sanofi Company Identifier: NCT00464321     History of Changes
Other Study ID Numbers: GC1008FSGS00505 
Study First Received: April 20, 2007
Last Updated: March 17, 2014
Health Authority: United States: Food and Drug Administration
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Germany: Paul-Ehrlich-Institut
Italy: National Institute of Health

Additional relevant MeSH terms:
Glomerulosclerosis, Focal Segmental
Kidney Diseases
Urologic Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on December 08, 2016